Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
BioConferenceLive

Illumina Agrees to Acquire Genomic Informatics Company, Strengthens IT Portfolio

By BiotechDaily International staff writers
Posted on 12 Nov 2013
Illumina, Inc. (San Diego, CA, USA) has signed an agreement to acquire NextBio (Santa Clara, CA, USA), a developer of clinical and genomic informatics. NextBio’s comprehensive big-data platforms aggregate and analyze large quantities of phenotypic and genomic data for research and clinical applications.

With the addition of NextBio’s platform upon completion of the acquisition, Illumina will be able to offer customers enterprise level bioinformatics systems that will advance the discovery of new correlations between the human genome and disease, and finally, enable the application of those discoveries within healthcare.

“This agreement with NextBio demonstrates Illumina’s unwavering commitment to drive the adoption of sequencing in new markets and vastly improve the genomic information workflow,” said Jay Flatley, president and CEO of Illumina. “NextBio enables the classification and aggregation of phenotypic and clinical data within a single environment and allows analysis of that data at unprecedented speed and scale. The combination of Illumina’s BaseSpace cloud computing environment for next-generation sequencing with NextBio's platform for integrating patient data will allow us to deliver solutions that seamlessly integrate the entire workflow from sample to result.”

NextBio’s platform allows customers to quickly compare their experimental results against thousands of published and private data sets via a novel correlation engine, which precomputes billions of significant connections between disparate data components and helps discover new correlations. NextBio Clinical, which in 2012 passed an independent HIPAA audit, is designed for seamless integration with existing clinical and research systems. Backed by highly scalable software-as-a-service (SaaS) enterprise technology, it is capable of analyzing petabytes of data.

NextBio’s database platforms are currently used by researchers and clinicians in more than 50 commercial and academic institutions. NextBio will be incorporated into Illumina’s newly formed enterprise informatics business.

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. The company provides sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and proteins. Illumina also provides tools and services for consumer genomics and diagnostics.

Related Links:

Illumina 
NextBio



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel

Precise Ion Irradiation Dosing Method Developed for Cancer Therapy

Scientists are employing nuclear physics principles to provide more effective approaches to radiotherapy treatment for cancer patients. Radiation therapy using heavy ions is best suitable for cancer patients with tumors that are difficult to access, such as in the brain. These particles scarcely damage the penetrated... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.